The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 5
- Basım Tarihi: 2022
- Doi Numarası: 10.55730/1300-0144.5495
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.1551-1558
- Anahtar Kelimeler: Fulvestrant, hormone-positive, breast cancer, real-life, FALCON study, 500 MG, POSTMENOPAUSAL WOMEN, METAANALYSIS, TRASTUZUMAB, LETROZOLE, THERAPY
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Hacettepe Üniversitesi Adresli: Evet
Özet
Background/aim: We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort.